ILLUMINATE: Efficacy and Safety of Durvalumab/ Tremelimumab and Chemotherapy in EGFR-Mutant NSCLC Following Progression on EGFR Inhibitors

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [41] Patritumab deruxtecan shows activity in EGFR-mutant NSCLC
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (12) : 817 - 817
  • [42] Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
    Rose, Suzanne
    CANCER DISCOVERY, 2020, 10 (07) : 896 - 897
  • [43] Real world cfDNA collection in EGFR-mutant NSCLC
    Marcoux, N.
    Sequist, L. V.
    Hata, A.
    Banwait, M.
    Dagogo-Jack, I.
    Nagy, R.
    Lanman, R. B.
    Muzikansky, A.
    Digumarthy, S. R.
    Piotrowska, Z.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer
    Muthusamy, Bharathi
    Pennell, Nathan
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (02) : 179 - 181
  • [45] The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC
    Ardeshir-Larijani, Fatemeh
    Ramalingam, Suresh S.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (11) : 767 - 768
  • [46] Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
    Yan, Dan
    BIOMEDICINES, 2023, 11 (11)
  • [47] How I treat patients with EGFR-mutant NSCLC
    Aggarwal, Charu
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (11): : 387 - 387
  • [48] Patritumab deruxtecan shows activity in EGFR-mutant NSCLC
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2023, 20 : 817 - 817
  • [49] Rociletinib-associated cataracts in EGFR-mutant NSCLC
    Piotrowska, Z.
    Liu, E.
    Varga, A.
    Thakur, M.
    Narayanan, V.
    Liu, S. V.
    Neal, J.
    Spiegel, M.
    Solomon, B.
    Yu, H.
    Ou, S-H. I.
    Papadimitrakopoulou, V. A.
    Gadgeel, S.
    Camidge, D. R.
    Soria, J-C.
    Wakelee, H.
    Goldman, J.
    Kopani, K.
    Rolfe, L.
    Sequist, L. V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Overview of current systemic management of EGFR-mutant NSCLC
    Hsu, W. -H.
    Yang, J. C. -H.
    Mok, T. S.
    Loong, H. H.
    ANNALS OF ONCOLOGY, 2018, 29 : I3 - I9
12345